Overview
CJC-1295 is a long-acting GHRH analogue that may elevate GH levels 2–10× above baseline for approximately 6 days and increase IGF-1 by 1.5–3× for 9–11 days. GHRP-2 is a ghrelin-mimetic secretagogue with a plasma half-life of ~30 minutes that triggers rapid GH pulses peaking at ~25 minutes.
The combination leverages the acute pulsatile release from GHRP-2 with the sustained action of CJC-1295. This protocol presents a once-daily subcutaneous approach with practical dilution for clear measurements on an insulin syringe.
Reconstitution and Dilution
Standard concentration:
– Add 3.0 mL of bacteriostatic water
– Resulting concentration: ~3.33 mg/mL
– Equivalence: 1 unit ≈ 33.3 mcg
Steps:
1. Draw 3.0 mL of bacteriostatic water into a sterile syringe
2. Inject slowly along the vial wall; avoid foaming
3. Gently swirl or roll until dissolved (do not shake vigorously)
4. Label and refrigerate at 2–8°C, protected from light
Dosage Protocols
Standard/Gradual Approach
| Week | Daily Dose (mcg) | Daily Dose (mg) | Units (per injection) | Volume (mL) |
|---|---|---|---|---|
| 1–2 | 150 mcg | 0.15 mg | 4.5 units | 0.045 mL |
| 3–12 | 300 mcg | 0.30 mg | 9 units | 0.09 mL |
Frequency: Inject once daily subcutaneously, preferably at night or 30–60 minutes before sleep to coincide with the body’s natural nocturnal GH peak.
Advanced/Twice-Daily Approach
For protocols splitting the daily dose into two administrations (morning on an empty stomach; evening before sleep), ensuring doses are at least 3–8 hours apart:
| Week | Dose per Injection (mcg) | Dose per Injection (mg) | Units | Volume (mL) | Total Daily (mcg) |
|---|---|---|---|---|---|
| 1–2 | 100 mcg | 0.10 mg | 3 units | 0.03 mL | 200 mcg |
| 3–12 | 150 mcg | 0.15 mg | 4.5 units | 0.045 mL | 300 mcg |
Supplies Needed
For 8 weeks:
– 2 peptide vials
– 56 insulin syringes (7/week)
– 1 bacteriostatic water vial (10 mL)
– ~112 alcohol swabs (2 boxes of 100)
For 12 weeks:
– 3 peptide vials
– 84 insulin syringes
– 1 bacteriostatic water vial (10 mL)
– ~168 alcohol swabs (2 boxes of 100)
For 16 weeks:
– 4 peptide vials
– 112 insulin syringes
– 2 bacteriostatic water vials (10 mL each)
– ~224 alcohol swabs (3 boxes of 100)
Storage Instructions
Lyophilized:
– Refrigerate at 2–8°C (35.6–46.4°F)
– Freeze at −20°C (−4°F) for long-term storage beyond several months
Reconstituted:
– Refrigerate at 2–8°C (35.6–46.4°F)
– Use within 2–4 weeks for optimal potency
– Allow vials to reach room temperature before opening to reduce condensation absorption
– If longer storage is needed, aliquot into sterile containers and freeze once; avoid repeated freeze-thaw cycles
How It Works
CJC-1295 is a tetra-substituted GHRH(1–29) analogue engineered for extended half-life (~6–8 days) through protection against enzymatic degradation and reversible albumin binding. A single dose can sustain elevated GH for approximately 6 days and IGF-1 elevation for 9–11 days.
GHRP-2 is a synthetic ghrelin-mimetic hexapeptide that binds the GH secretagogue receptor (GHS-R1a), triggering acute GH pulses peaking at ~25 minutes. The combination of CJC-1295’s sustained GHRH signaling with GHRP-2’s rapid secretagogue action produces synergistic GH release exceeding either peptide alone.
Potential Benefits
Observations from pre-clinical and clinical literature:
– Sustained elevation of GH and IGF-1 levels during extended periods with once-daily or less frequent dosing
– Long-term pediatric studies (8 months) reported no significant adverse effects or toxicities from GHRP-2 therapy
– Enhanced synergism between sustained GHRH action and acute secretagogue pulses
Potential Side Effects
– GHRP-2 may transiently increase appetite due to ghrelin-like activity
– Mild transient elevations in ACTH, cortisol, and prolactin may occur shortly after injection, but remain within physiological ranges
– CJC-1295 at higher doses may cause transient vasodilatory effects such as facial flushing or brief dizziness
– Occasional mild injection site reactions (redness, itching) may occur with subcutaneous administration
Important Considerations
– Use new sterile insulin syringes for each injection; dispose in a sharps container
– Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation
– Inject slowly on an empty stomach; GHRP-2’s GH response may be attenuated by elevated blood glucose
– Document daily dose and site rotation to maintain consistency
– No post-cycle therapy required; GH and IGF-1 levels return to baseline after cessation
Injection Technique
– Clean vial and skin with alcohol; allow to dry
– Pinch a skin fold; insert needle at 45–90° into subcutaneous tissue
– Do not aspirate; inject slowly and steadily
– Systematically rotate sites (abdomen, thighs, upper arms) to avoid local tissue changes
– Withdraw needle at the same angle; dispose immediately in a sharps container
Lifestyle Factors
– Pair with a balanced, protein-rich diet tailored to energy and recovery needs
– Combine resistance training and aerobic activity to complement GH-mediated anabolic and metabolic effects
– Prioritize quality sleep; nocturnal GH secretion is enhanced by adequate rest
– Inject on an empty stomach or after a 2–3 hour fast; carbohydrate-rich meals may attenuate the GHRP-2 GH response
Disclaimer
This content is intended exclusively for educational and therapeutic purposes and does not constitute medical advice, diagnosis, or treatment. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before initiating any research protocol.